Wolfe v. McNeil-PPC, Inc.

703 F. Supp. 2d 487, 2010 U.S. Dist. LEXIS 77604, 2010 WL 3025805
CourtDistrict Court, E.D. Pennsylvania
DecidedJuly 30, 2010
DocketCivil Action 07-348
StatusPublished
Cited by7 cases

This text of 703 F. Supp. 2d 487 (Wolfe v. McNeil-PPC, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Wolfe v. McNeil-PPC, Inc., 703 F. Supp. 2d 487, 2010 U.S. Dist. LEXIS 77604, 2010 WL 3025805 (E.D. Pa. 2010).

Opinion

MEMORANDUM

DUBOIS, District Judge.

I. INTRODUCTION

This is a products liability action in which plaintiff, Kiley Wolfe, alleges that the Children’s Motrin manufactured and marketed by defendants caused her to develop Stevens-Johnson Syndrome and Vanishing Bile Duct Syndrome. The Court’s Third Amended Scheduling Order of March 30, 2009, directed the parties to file and serve memoranda of law addressing their respective positions on the choice of law issues in the case. After reviewing those memoranda and the relevant material submitted by the parties, the Court concludes that Pennsylvania law is applicable to Counts One through Six of the Complaint and that Maine law will be applied to Count Seven and the affirmative defense of comparative negligence.

II. BACKGROUND

Kiley Wolfe contracted a virus while living with her parents in Bath, Maine during the Spring and Summer of 1996, when she was nine years old. (Compl. ¶¶ 2, 21, 22.) Sometime around May 27, 1996, Wolfe’s parents took her to see a pediatrician in Maine. The pediatrician prescribed Children’s Motrin to help relieve Wolfe’s symptoms, which included headache, stomach pains, and a fever. (Compl. ¶ 21, 22). Children’s Motrin is an over-the-counter non-steroidal anti-inflammatory analgesic drug, generically referred to as ibuprofen, manufactured and marketed by defendants. (Compl. ¶ 12.)

Despite taking the Children’s Motrin, Wolfe’s symptoms did not improve. Instead, a rash formed on her face and she was again taken to see her Maine pediatrician, who continued to prescribe Children’s Motrin (Compl. ¶ 24, 25). Thereafter, hundreds of tiny blisters appeared on Wolfe’s face, ears and throat. (Compl. ¶ 27.) Sometime after June 1, 1996, Wolfe was taken to Boston Children’s Hospital by her mother, where she was diagnosed with Stevens-Johnson Syndrome, which led to the development of Acute Vanishing Bile *491 Duct Syndrome. (Compl. ¶¶ 28, 29, 30). Since this diagnosis, Wolfe has been treated at locations in Ohio, Florida, and Louisiana, the state where she currently resides.

Each of the defendants is alleged to be involved in the design, testing, manufacturing, marketing and selling of Children’s Motrin. McNeil-PPC is New Jersey Corporation with its principal place of business in New Jersey; McNeil Consumer Healthcare 1 is an unincorporated division of McNeil-PPC with a headquarters in Fort Washington, Pennsylvania; Johnson & Johnson, Inc. is the parent company of Johnson & Johnson Pharmaceutical Research and Development and the parent company of McNeil-PPC and McNeil Consumer Healthcare. The Johnson & Johnson companies are both New Jersey corporations with principal places of business in New Jersey.

Plaintiffs Complaint contains seven counts: (1) negligence, (2) strict liability under Restatement (Second) of Torts § 402A, (3) strict liability under Restatement (Second) of Torts § 402B, (4) breach of express warranty, (5) breach of implied warranty of merchantability, (6) violation of consumer protection law, and (7) punitive damages. Plaintiff avers that the conduct for which it seeks to hold defendants liable took place at McNeil Consumer Healthcare’s headquarters in Fort Washington, Pennsylvania.

III. DISCUSSION

Plaintiff and defendants agree that the first five counts of the Complaint do not present any true conflicts of law. Thus, applying Pennsylvania choice of law rules, Pennsylvania law will be applied to those counts of the Complaint. See Hammersmith v. TIG Ins. Co., 480 F.3d 220, 226-27 (3d Cir.2007) (noting that a deep choice of law analysis is only necessary under Pennsylvania choice of law rules if there is a true conflict) (citing Cipolla v. Shaposka, 439 Pa. 563, 267 A.2d 854, 856 (1970)).

With respect to Count Six, the consumer protection law claim, the parties agree that, although there is a true conflict between the consumer protection laws of Maine and Pennsylvania, Pennsylvania law should be applied. Accordingly, the Court need not conduct a choice-of-law analysis regarding Count Six. See Health Robotics, LLC v. Bennett, No. 09-627, 2009 WL 5033966, at *2 n. 2 (E.D.Pa. Dec. 22, 2009). Pennsylvania law will be applied to Count Six.

The clash in this case concerns Count Seven — the punitive damages claim — and defendant’s affirmative defense of comparative negligence. The parties dispute whether there is a true conflict between the laws of Pennsylvania and Maine and, if so, which jurisdiction has the greater interest in having its laws applied. The Court addresses each of these issues in turn.

A. Principles Governing Choice of Law Analysis in Pennsylvania

Federal courts exercising diversity jurisdiction must apply the conflict of law rules of the forum state. On Air Entm’t Corp. v. Nat’l Indem. Co., 210 F.3d 146, 149 (3d Cir.2000) (citing Klaxon Co. v. Stentor Elec. Mfg. Co., 313 U.S. 487, 496-97, 61 S.Ct. 1020, 85 L.Ed. 1477 (1941)). Therefore, Pennsylvania choice of law rules apply to this case.

*492 Pennsylvania applies “interest/contacts” methodology to choice-of-law questions. See Hammersmith, 480 F.3d at 226-27. This is a “flexible choice of law rule which weighs the interests [its] sister-states may have in the transaction.” Powers v. Lycoming Engines, 328 Fed.Appx. 121, 124 (3d Cir.2009) (quoting Commonwealth v. Eichinger, 591 Pa. 1, 915 A.2d 1122, 1133 (2007)). Pennsylvania’s choice-of-law analysis requires the Court to conduct a two-part inquiry: “The first level of scrutiny considers whether ‘an actual or real conflict [exists] between the potentially applicable laws.’ ” Powers, 328 Fed.Appx. at 125 (quoting Hammersmith, 480 F.3d at 230) (brackets added in Powers). “If there are relevant differences between the laws, then the court should examine the governmental policies underlying each law, and classify the conflict as a ‘true,’ ‘false,’ or an ‘unprovided-for’ situation.’ ” Hammersmith, 480 F.3d at 230.

Whether a conflict is true or false depends on each jurisdiction’s interest in having its law applied. If “only one jurisdiction’s governmental interests would be impaired by the application of the other jurisdiction’s law,” then the conflict is a false one and “the court must apply the law of the state whose interests would be harmed if its law were not applied.” Lacey v. Cessna Aircraft Co., 932 F.2d 170, 187 (3d Cir.1991).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Knight v. Avco Corporation
M.D. Pennsylvania, 2025
Hochendoner v. Genzyme Corp.
95 F. Supp. 3d 15 (D. Massachusetts, 2015)
Brown v. Johnson
64 F. Supp. 3d 717 (E.D. Pennsylvania, 2014)
Rowland v. Novartis Pharmaceuticals Corp.
983 F. Supp. 2d 615 (W.D. Pennsylvania, 2013)
Wolfe v. McNeil-PPC, Inc.
773 F. Supp. 2d 561 (E.D. Pennsylvania, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
703 F. Supp. 2d 487, 2010 U.S. Dist. LEXIS 77604, 2010 WL 3025805, Counsel Stack Legal Research, https://law.counselstack.com/opinion/wolfe-v-mcneil-ppc-inc-paed-2010.